Navigation Links
Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
Date:10/20/2009

d US $1,240,405, or 96% of revenue for the quarter, up from $865,407 for the first quarter in 2008.

"Sinobiopharma has reached two important milestones," said Dr. Huang. "First, its wholly owned operating subsidiary, Dong Ying (Jiangsu) has recorded more than one half million USD net income in a quarter; and second, the Company has posted an overall net profitable result in its consolidated financial statement for the first time since the second quarter 2008."

"The increases in sales revenue, as well as those in gross and net profit, are clear indicators that more hospitals are choosing our products over those of our competitors, that our continuing efforts to control costs are succeeding, and that our sales and marketing efforts are bearing fruit. We will continue executing on our plan to improve production efficiencies while expanding sales and marketing to ensure that more patients benefit from our products," said Dr. Huang.

About Sinobiopharma

Sinobiopharma, Inc. is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or b
'/>"/>

SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
2. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
3. Sinobiopharma, Inc. Appoints New Director of Marketing
4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
6. Sinobiopharma Secures Rights to Seven Key Patents
7. Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
8. Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009
9. Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate
10. Emissary Capital Group Initiates Coverage on Sinobiopharma
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Incorporated (SPEX) -- an intellectual property development company committed to ... the United States Patent & Trademark Office (USPTO) issued a ... that is part of a standard essential family of patents. ... , Application number: US 13/728,867 , Publication date: Sep ... The listed inventors of the new patent, entitled ...
(Date:9/20/2014)... Massachusetts, USA (PRWEB) September 20, 2014 ... prestigious 2015 Prism Awards for Photonics Innovation . ... from the multi-billion dollar optics and photonics industry, and ... optics and photonics , and Photonics Media . ... as the versatility of photonics, said SPIE CEO Eugene ...
(Date:9/19/2014)... is rarely simple. From crop yields to disease risks, ... those considered "complex traits." Just as for heightthe textbook ... particular human disease are shaped by multiple genetic and ... involved. To track down such genes, geneticists typically mate ... large mouse and a small mouseand then study their ...
(Date:9/19/2014)... Sept. 19, 2014  An entire month is dedicated ... neuropathies – Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular ... extreme muscle atrophy, weakness, and foot and hand deformities. ... millions worldwide. CMT is a progressive disease, and over ... requiring mobility devices such as leg braces, wheelchairs and ...
Breaking Biology Technology:Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3Entry deadline is 10 October for international photonics Prism Awards 2Entry deadline is 10 October for international photonics Prism Awards 3Entry deadline is 10 October for international photonics Prism Awards 4Want to link genes to complex traits? Start with more diversity 2September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2
... , , INDIANAPOLIS, Sept. 2 ... announced that, effective October 1, 2009, it would increase the ... kg for all non-contract customers or as existing contracts permit. ... invest in expanding global supply for the high performance, reducing ...
... WILMINGTON, Delaware, September 2 According ... (2009 - 2014), published,by MarketsandMarkets ( http://www.marketsandmarkets.com ), ... US$19.4 billion by 2014, recording,a CAGR of 89.1% ... patients,insurers, and government agencies to reduce the costs ...
... , SOUTH PLAINFIELD, N.J., Sept. 2 ... and licensing agreement with Roche for the development of orally bioavailable ... (GEMS(TM)). The collaboration focuses initially on four CNS disease targets ... (Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ) , , ...
Cached Biology Technology:MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014 2MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014 3PTC Therapeutics Announces Drug Discovery Collaboration With Roche 2PTC Therapeutics Announces Drug Discovery Collaboration With Roche 3
(Date:9/21/2014)... researchers has developed a protein therapy that disrupts the ... original tumor sites, travel through the blood stream and ... This process, known as metastasis, can cause cancer to ... patients who succumb to cancer fall prey to metastatic ... professor of bioengineering who describes a new therapeutic approach ...
(Date:9/19/2014)... fairness did not evolve for the sake of fairness ... of continued cooperation, so say Frans de Waal, PhD, ... about inequity aversion (IA), which is defined as a ... in Science . , Their conclusion comes ... to address their hypothesis that it is the evolution ...
(Date:9/18/2014)... new GSA Bulletin study uses tree rings ... and Chaco Wash in northern New Mexico, USA. By ... and willow, investigators were able to precisely date arroyo ... combined this data with aerial imagery, LiDAR, longitudinal profiles, ... arroyos. , Arroyos are deep, oversized channels that have ...
Breaking Biology News(10 mins):Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7
... build tannins, complex chemicals used by plants for defence ... discovered organelle that is found in most land plants. ... they are single-celled organisms like amoeba, or enormous entities ... up the body of the organism). Although cells may ...
... University of Alberta have made a basic science discovery ... When DNA becomes too damaged it ultimately leads to ... Glover and his colleagues published their findings in the ... summer. For years, scientists thought two key proteins involved ...
... landmark study that has discovered four novel gene variations ... meta-analysis, involving nearly 30,000 African-Americans, also found that the ... pressure across other populations. Epidemiology and biostatistics ... paper, which appears in The American Journal of ...
Cached Biology News:New cell component important to tea and wine-making 2Discovery about DNA repair could lead to improved cancer treatments 2African-American study identifies 4 genetic variants associated with blood pressure 2
FluoSpheres® biotin-labeled microspheres, 0.2 µm, yellow-green fluorescent (505/515) *1% solids*...
GM130 Immunogen: Recombinant purified rat GM130 Family / Subclass 1: Signal Transduction Storage: 4 C...
... Anti-NY-ESO-1, clone E978 ... : NM_001327 Immunogen ... protein Formulation: mouse ascites ... Quality Assurance: routinely evaluated ...
R26.4C...
Biology Products: